Form 4: Supernus Director Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Supernus Pharmaceuticals Director Charles W. Newhall III sold 1,000 shares of common stock for a weighted average price of $45.00 under a pre-arranged 10b5-1 trading plan.
Summary
- Charles W. Newhall III, a Director of Supernus Pharmaceuticals, Inc. (SUPN), reported a sale of common stock.
- The transaction involved the disposition of 1,000 shares of common stock.
- The shares were sold at a weighted average price of $45.00, with individual transactions ranging from $45.00 to $45.01 per share.
- This sale was executed on August 25, 2025, pursuant to a Rule 10b5-1 trading plan adopted on March 3, 2025.
- Following this transaction, Mr. Newhall beneficially owns 133,232 shares of Supernus common stock directly.
Sentiment
Score: 5
Explanation: The sale of shares by a director is generally viewed as neutral to slightly negative. However, the execution under a pre-arranged 10b5-1 plan mitigates any negative implications, as it suggests a planned liquidity event rather than a reaction to adverse company-specific news.
Positives
- The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned sale rather than a reaction to recent events or non-public information.
Negatives
- A director selling shares, even under a 10b5-1 plan, reduces their direct ownership stake in the company.
Future Outlook
No forward-looking statements or guidance are provided in this Form 4 filing.
Industry Context
This Form 4 filing reports an individual insider transaction and does not provide information directly related to broader industry trends or competitive landscape within the pharmaceutical sector.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan | Director Charles W. Newhall III executed a sale of common stock under a Rule 10b5-1 trading plan, which was adopted on March 3, 2025. This plan allows insiders to set up a pre-arranged schedule for buying or selling company stock to avoid accusations of insider trading. | 03/03/2025 | Enhances transparency and provides an affirmative defense against insider trading allegations for the reporting person. |
Stakeholder Impact
- Shareholders: A minor reduction in director ownership, but the 10b5-1 plan suggests it is a planned event rather than a signal of lack of confidence. The small volume of shares sold is unlikely to significantly impact market perception.
Key Dates
| Date | Description |
|---|---|
| 03/03/2025 | Date the 10b5-1 trading plan was adopted. |
| 08/25/2025 | Date of the common stock transaction (sale). |
| 08/27/2025 | Date the Form 4 was signed by attorney-in-fact. |
Recommendation
holdThis Form 4 filing reports a routine, pre-scheduled insider sale of a relatively small number of shares by a director. Such a transaction, especially under a 10b5-1 plan, typically does not provide new material information that would warrant a change in investment recommendation for Supernus Pharmaceuticals. Investors should continue to evaluate the company based on its fundamental performance, financial reports, and strategic outlook.
Keywords
Supernus Pharmaceuticals, SUPN, Insider Trading, Form 4, Director Sale, 10b5-1 Plan, Charles W. Newhall III, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.